Last updated: August 1, 2026
Cialis (tadalafil) is a mature phosphodiesterase-5 inhibitor marketed by Eli Lilly for erectile dysfunction and benign prostatic hyperplasia. Its U.S. composition and use patents have expired, generic tadalafil is widely available, and no biosimilar pathway applies. Current clinical development is concentrated on tadalafil’s established indications, pulmonary arterial hypertension under the Adcirca brand, combination therapy, and new erectile-dysfunction delivery formats rather than on new Cialis exclusivity.
What is the current FDA status of Cialis?
Cialis contains tadalafil, a selective PDE5 inhibitor that increases cyclic guanosine monophosphate activity and promotes smooth-muscle relaxation.
| Attribute |
Status |
| Active ingredient |
Tadalafil |
| Original developer |
ICOS Corporation, later acquired by Eli Lilly |
| U.S. approval |
November 21, 2003 |
| U.S. indications |
Erectile dysfunction; signs and symptoms of benign prostatic hyperplasia; combined ED and BPH |
| Approved strengths |
2.5 mg, 5 mg, 10 mg, and 20 mg |
| Daily-use dose |
Typically 2.5 mg or 5 mg |
| As-needed dose |
Typically 10 mg or 20 mg |
| Regulatory category |
Small-molecule prescription drug |
| U.S. generic status |
Approved and marketed |
| Biologic or biosimilar status |
Not applicable |
The FDA approved Cialis for erectile dysfunction in 2003 and later approved once-daily Cialis for BPH and combined ED/BPH treatment. The drug is contraindicated with organic nitrates because the combination can cause a clinically significant reduction in blood pressure. Tadalafil also has warnings involving alpha blockers, antihypertensive medicines, alcohol, cardiovascular disease, sudden vision loss, sudden hearing loss, and priapism. (U.S. Food and Drug Administration, 2003)
Tadalafil is also approved as Adcirca for pulmonary arterial hypertension. The Adcirca label uses a 40 mg once-daily dose, which differs from Cialis dosing. The same active ingredient is marketed under different trade names and regulatory indications. (U.S. Food and Drug Administration, 2009)
What clinical trials are evaluating tadalafil?
Clinical research on tadalafil is mature, with most large efficacy questions already addressed. Recent and ongoing studies generally examine long-term safety, treatment combinations, special populations, alternative formulations, and use in conditions beyond the Cialis label.
Erectile dysfunction and benign prostatic hyperplasia
The established clinical evidence supports:
- As-needed tadalafil for erectile dysfunction.
- Once-daily tadalafil for erectile dysfunction.
- Once-daily tadalafil for lower urinary tract symptoms associated with BPH.
- Combined treatment for men with both erectile dysfunction and BPH symptoms.
- Efficacy across a broad range of ages and comorbidities, including diabetes and hypertension.
Tadalafil’s commercial differentiation from sildenafil historically came from its longer duration of action. The terminal half-life is approximately 17.5 hours, and clinical effects may persist for up to 36 hours in some patients. This profile supports both as-needed and daily dosing. (U.S. Food and Drug Administration, 2003)
Pulmonary arterial hypertension
Tadalafil’s PAH development is separate from the Cialis franchise but materially relevant to the molecule’s clinical profile. The PHIRST trial demonstrated improvement in six-minute walk distance and clinical outcomes at a 40 mg daily dose. Tadalafil competes with sildenafil, riociguat, endothelin-receptor antagonists, prostacyclin therapies, and combination regimens. (Galiè et al., 2009)
Later PAH research has increasingly focused on combination therapy rather than tadalafil monotherapy. The competitive importance of tadalafil in PAH has been reduced by generic availability and by newer combination products, including fixed-dose ambrisentan/tadalafil products in some markets.
New indications and exploratory research
Tadalafil has been investigated in multiple non-Cialis conditions, including:
- Lower urinary tract symptoms unrelated to classic BPH.
- Female sexual arousal and related sexual-function disorders.
- Raynaud’s phenomenon.
- Heart failure and vascular disease.
- Prostate cancer and radiation-related erectile dysfunction.
- Neurogenic erectile dysfunction.
- Exercise-related vascular disorders.
These studies have not produced a new, high-value FDA indication comparable to the original ED approval. Clinical-trial activity should therefore be viewed as lifecycle research with limited potential to restore Cialis-level revenue unless a sponsor secures a new indication and differentiated formulation.
What is the current clinical-trial outlook?
The commercial clinical-trial outlook is limited for branded Cialis. Tadalafil has extensive postmarketing exposure, a well-characterized safety profile, and a large generic evidence base. New trials are more likely to support:
- Combination treatment in BPH or PAH.
- Specialty populations with inadequate response to PDE5 inhibitors.
- Alternative delivery systems.
- Real-world safety and adherence.
- Off-label or investigational vascular applications.
ClinicalTrials.gov records should be reviewed by intervention, sponsor, recruitment status, and primary completion date because the tadalafil trial portfolio changes as studies are completed or withdrawn. No clinical-trial program can reverse the core U.S. loss of small-molecule exclusivity for Cialis.
When did Cialis lose patent exclusivity?
Cialis lost effective U.S. market exclusivity before the expiration of every secondary patent because Eli Lilly entered into settlement arrangements with generic manufacturers.
The main U.S. patent history is summarized below.
| Patent or regulatory protection |
Subject matter |
Reported U.S. expiration or effective loss |
| U.S. Patent No. 5,985,889 |
Tadalafil compound and related protection |
2017, subject to patent-term adjustments and commercial settlement history |
| U.S. Patent No. 6,821,975 |
Tadalafil use and related pharmaceutical claims |
2020 |
| U.S. Patent No. 6,943,166 |
Tadalafil-related use or formulation claims |
Around 2020, depending on claim and listing |
| Pediatric exclusivity |
Added six months to eligible listed protections |
Applied to certain listed patents |
| Generic settlement |
Authorized earlier generic entry |
August 2018 for several manufacturers |
Patent expiration dates depend on the specific patent, patent-term adjustment, pediatric exclusivity, listed claim, and jurisdiction. A single “Cialis patent expiration date” is therefore incomplete. The commercially important event was the settlement-enabled generic launch in 2018, not only the later nominal expiration of secondary patents.
Which companies challenged Cialis patents?
Several generic manufacturers obtained U.S. approval or launch rights through Abbreviated New Drug Application proceedings and patent settlements. Companies associated with U.S. tadalafil products include:
- Teva Pharmaceuticals.
- Apotex.
- Mylan, now part of Viatris.
- Amneal Pharmaceuticals.
- Torrent Pharmaceuticals.
- Zydus Pharmaceuticals.
- Dr. Reddy’s Laboratories.
- Endo or Par Pharmaceutical entities.
- Other ANDA sponsors approved over time.
Generic applicants typically used Paragraph IV certifications for listed Cialis patents. Under the Hatch-Waxman Act, a Paragraph IV certification asserts that a listed patent is invalid, unenforceable, or not infringed. Filing a Paragraph IV notice can trigger patent litigation and a potential 30-month stay of FDA approval under applicable statutory conditions. (U.S. Food and Drug Administration, 2024a)
What was the Cialis patent settlement?
Eli Lilly reached settlements with generic manufacturers that allowed earlier generic tadalafil entry than would have occurred under full enforcement of all asserted patent rights. Generic entry began in the United States in August 2018. The settlement structure reduced litigation uncertainty and converted a later patent cliff into a controlled, multi-manufacturer launch.
The economic effect was substantial. Eli Lilly retained brand sales before settlement-authorized entry, while generic manufacturers gained a defined launch date and avoided prolonged patent litigation. Public settlement terms varied by company and were not identical across all generic applicants.
What is the Orange Book status of Cialis?
Cialis is listed in the FDA Orange Book as a prescription drug with tadalafil as its active ingredient. Historically listed patents covered the tadalafil compound, pharmaceutical compositions, and methods of use for erectile dysfunction and BPH.
The practical Orange Book analysis requires separating:
- Patents listed against the Cialis NDA.
- Patents still within their enforceable term.
- Patents with claims relevant to the proposed generic label.
- Pediatric exclusivity.
- Label carve-outs for protected methods.
- Patents listed against Adcirca rather than Cialis.
A generic tadalafil applicant can receive approval with labeling that omits a protected method of use, subject to FDA requirements. This is especially relevant where the generic seeks approval for ED, BPH, or both and the reference product has multiple indications.
What formulations are protected by Cialis patents?
Cialis is an immediate-release oral tablet. Its formulation protection is less commercially durable than its active-ingredient and method-of-use protection.
Potentially relevant formulation and product attributes include:
- Tadalafil particle characteristics.
- Oral solid dosage forms.
- Tablet excipients and manufacturing processes.
- Dose strengths from 2.5 mg through 20 mg.
- Once-daily dosing.
- Rapid-dissolution or orally disintegrating presentations.
- Combination products involving tadalafil and another active ingredient.
Generic tadalafil tablets do not need to reproduce every inactive ingredient used in Cialis. They must meet pharmaceutical equivalence and bioequivalence requirements for the approved product and comply with applicable ANDA standards.
Are there new tadalafil delivery systems?
Alternative formulations, including orally disintegrating tablets, sublingual products, chewable tablets, and compounded presentations, have been developed or studied in different markets. These products may create formulation or manufacturing patent opportunities, but they do not restore broad composition-of-matter exclusivity over tadalafil.
The strongest remaining IP position for a new delivery system would normally depend on claim scope, clinical differentiation, freedom-to-operate analysis, and whether the product can support a new regulatory indication.
How strong is the Cialis patent estate?
The current U.S. patent estate is weak for broad tadalafil protection and stronger only for narrow, jurisdiction-specific claims.
| Patent category |
Current strength |
| Tadalafil composition of matter |
Expired or commercially exhausted in the United States |
| Standard Cialis tablet |
Low |
| ED method of use |
Low after generic entry |
| BPH method of use |
Low to moderate for narrow label or jurisdiction-specific claims |
| Novel formulation |
Potentially moderate if claims are valid and differentiated |
| Manufacturing process |
Potentially moderate, but difficult to enforce against unobservable processes |
| Combination therapy |
Potentially stronger for a genuinely novel combination |
| PAH indication |
Generic and branded competition; limited broad exclusivity |
| Non-U.S. rights |
Varies materially by country |
Process patents can create manufacturing barriers where the claimed process is difficult to detect or where regulatory filings disclose process details. They generally do not prevent all manufacturers from producing tadalafil through an alternative process.
What generic entry risks exist for Cialis?
Generic entry risk is high because tadalafil is an established small molecule with:
- Extensive clinical use.
- Multiple approved generic suppliers.
- Straightforward oral-tablet dosage forms.
- No biosimilar comparability requirement.
- Limited remaining U.S. patent protection.
- Strong pharmacy substitution incentives.
- Significant historical price erosion.
Generic competition can still be constrained by manufacturing quality, supply interruptions, controlled distribution, foreign regulatory requirements, or product-specific formulation claims. Those factors do not materially change the broad U.S. conclusion: standard Cialis has high generic substitution risk.
Does Cialis face biosimilar competition?
No. Cialis is a chemically synthesized small molecule, not a biologic. The relevant competitive pathway is the ANDA generic pathway, not the Biologics Price Competition and Innovation Act biosimilar pathway. Tadalafil competitors are evaluated for pharmaceutical equivalence and bioequivalence rather than biosimilarity.
How does Cialis compare with Viagra and Levitra?
| Product |
Active ingredient |
Approximate duration |
U.S. commercial status |
Main differentiation |
| Cialis |
Tadalafil |
Up to 36 hours of potential effect |
Brand plus generics |
Long duration; daily dosing; BPH indication |
| Viagra |
Sildenafil |
About 4 to 6 hours |
Brand plus generics |
Earlier market entry; broad physician familiarity |
| Levitra/Staxyn |
Vardenafil |
About 4 to 5 hours |
Limited brand presence; generic availability |
PDE5 class alternative |
| Stendra |
Avanafil |
Shorter onset in some studies |
Brand product |
Potential onset and tolerability positioning |
Cialis has the strongest commercial differentiation in duration and daily BPH treatment. Viagra has stronger historical brand recognition. Generic prices for all major PDE5 inhibitors have reduced the value of brand-only positioning.
What is the Cialis market size and revenue exposure?
Cialis was one of Eli Lilly’s major products before generic entry. Lilly reported approximately $2.3 billion in Cialis revenue in 2017, followed by a sharp decline after generic competition began. Reported revenue fell to roughly $1.9 billion in 2018 and continued declining in subsequent years as generic tadalafil captured volume. Exact year-to-year figures vary with currency, geography, channel mix, and the treatment of certain commercial arrangements. (Eli Lilly and Company, 2018, 2019, 2020)
The global tadalafil market remains materially larger than branded Cialis sales because it includes:
- Generic tadalafil.
- Cialis.
- Adcirca and generic tadalafil for PAH.
- Hospital and specialty distribution.
- Retail and online pharmacy channels.
- Compounded or locally registered presentations in selected jurisdictions.
Commercial market research firms generally project continued growth in the broader tadalafil or erectile-dysfunction drug market through 2030, with estimates varying widely by market definition. Forecast drivers include aging populations, improved diagnosis, telehealth prescribing, increased treatment of diabetes and cardiovascular comorbidities, and demand for once-daily therapy. Generic price erosion limits revenue growth even when prescription volume rises.
What is the Cialis market projection through 2030?
The branded Cialis market is expected to remain mature and structurally smaller than its pre-generic peak. The broader tadalafil market is likely to grow in units but face declining average selling prices.
| Period |
Expected market condition |
| 2025-2026 |
High generic penetration; stable demand; limited branded growth |
| 2027-2028 |
Continued volume growth in ED and BPH; price competition intensifies |
| 2029-2030 |
Growth concentrated in emerging markets, telehealth, PAH, and differentiated formulations |
| Long-term |
Generic tadalafil remains the volume leader; brand value depends on access, packaging, and physician preference |
Commercial forecasts should be interpreted as market-sizing estimates, not audited product revenue. The most defensible investment thesis is volume expansion with margin compression, not a return of Cialis to its pre-2018 revenue level.
What licensing and commercial deals affect tadalafil?
The principal commercial history involves ICOS and Eli Lilly. Eli Lilly and ICOS developed Cialis before Lilly acquired ICOS in 2007. That transaction consolidated control of the Cialis franchise and related tadalafil assets within Lilly. (Eli Lilly and Company, 2007)
Tadalafil has also been commercialized through licensing, regional partnerships, and authorized generic arrangements. PAH commercialization has involved separate brand and partner structures from the Cialis ED/BPH business. Rights must be analyzed by product, indication, country, and dosage form because an agreement covering Adcirca or a regional tadalafil product may not cover Cialis.
What patent litigation affects Cialis?
The principal litigation risk was concentrated before generic entry and involved Paragraph IV challenges to Orange Book-listed Cialis patents. After authorized and settlement-based generic entry, the litigation profile shifted from broad molecule protection to narrower disputes involving:
- Label scope.
- Formulation claims.
- Manufacturing methods.
- Regional patents.
- ANDA certification language.
- Indication carve-outs.
- Contractual settlement terms.
No current litigation posture should be inferred solely from historical Cialis cases. Generic products may face separate litigation concerning manufacturing, trademarks, packaging, or non-tadalafil patents.
What are the geographic patent and market differences?
U.S. generic entry occurred in 2018, but patent expiry and launch timing varied by jurisdiction. European and other markets experienced generic tadalafil competition at different times based on national patent terms, supplementary protection certificates, pediatric extensions, regulatory approvals, and local litigation.
Geographic commercial considerations include:
- Earlier generic entry in some European markets.
- Different reference-product requirements.
- National substitution rules.
- Variable reimbursement for ED and BPH.
- Local patent term adjustments.
- Different treatment of second medical use claims.
- Stronger or weaker online-pharmacy enforcement.
- Country-specific manufacturing and import rules.
The United States remains the most important reference market for Hatch-Waxman patent strategy, while Europe and emerging markets provide volume opportunities with lower average prices.
What generic launch scenarios are most likely?
The base case is continued broad generic availability of tadalafil tablets, with competition among multiple suppliers and limited ability for the Cialis brand to sustain premium pricing.
| Scenario |
Probability profile |
Commercial effect |
| Base case |
Multiple generic suppliers remain active |
Persistent price erosion and stable unit demand |
| Upside case |
Growth in BPH diagnosis, telehealth, and daily dosing |
Higher tadalafil volume, limited brand recovery |
| Downside case |
Supply consolidation, safety concerns, or reimbursement restrictions |
Lower access and reduced market value |
| Innovation case |
New formulation or combination gains approval |
Localized premium opportunity, not molecule-wide exclusivity |
Key Takeaways
- Cialis is tadalafil, a mature small-molecule PDE5 inhibitor approved for ED and BPH.
- U.S. generic tadalafil entered in August 2018 following patent settlements.
- Broad Cialis composition and use protection is no longer a meaningful barrier to U.S. generic competition.
- No biosimilar risk applies; the relevant pathway is ANDA approval.
- Ongoing tadalafil research focuses on combination therapy, PAH, special populations, long-term safety, and alternative formulations.
- Lilly’s Cialis revenue declined sharply after generic entry.
- The broader tadalafil market should grow mainly through prescription volume, while generic competition compresses prices.
- The strongest remaining IP opportunities are narrow formulation, combination, manufacturing, and jurisdiction-specific claims.
- Standard Cialis tablets have high generic substitution risk and limited prospects for restoring pre-2018 branded revenue.
FAQs About Cialis Patents, Trials and Market Outlook
Does tadalafil still have patent protection in the United States?
Broad U.S. protection for tadalafil and standard Cialis use has expired or been commercially exhausted. Narrow patents may remain relevant for particular formulations, combinations, processes, or uses.
Can a generic manufacturer sell tadalafil for BPH?
Yes. Generic tadalafil may be approved for BPH where the applicant satisfies FDA requirements and addresses applicable listed patents, including through a permitted label carve-out.
Is Adcirca covered by the same patents as Cialis?
Not necessarily. Adcirca and Cialis contain tadalafil but have different indications, dosage strengths, labeling, and NDA histories. Patent and Orange Book analysis must be performed separately.
Can tadalafil be reformulated into a new exclusivity product?
A new formulation may receive patent protection and, depending on the clinical and regulatory strategy, additional market protection. It would not recreate composition-of-matter exclusivity for tadalafil itself.
Will Cialis sales recover after telehealth expansion?
Telehealth can increase tadalafil prescriptions, but most incremental volume is likely to benefit generic manufacturers. Brand recovery depends on formulary access, pricing, physician preference, and differentiated product positioning.
References
-
Eli Lilly and Company. (2007). Annual report 2006. Indianapolis, IN: Author.
-
Eli Lilly and Company. (2018). Annual report 2017. Indianapolis, IN: Author.
-
Eli Lilly and Company. (2019). Annual report 2018. Indianapolis, IN: Author.
-
Eli Lilly and Company. (2020). Annual report 2019. Indianapolis, IN: Author.
-
Galiè, N., Brundage, B. H., Ghofrani, H. A., Oudiz, R. J., Simonneau, G., Safdar, Z., Shapiro, S., White, R. J., Chan, M., Beardsworth, A., Frumkin, L., Barst, R. J., & Pulmonary Arterial Hypertension and Response to Tadalafil Study Group. (2009). Tadalafil therapy for pulmonary arterial hypertension. Circulation, 119(22), 2894-2903.
-
U.S. Food and Drug Administration. (2003). Cialis (tadalafil) prescribing information. Silver Spring, MD: Author.
-
U.S. Food and Drug Administration. (2009). Adcirca (tadalafil) prescribing information. Silver Spring, MD: Author.
-
U.S. Food and Drug Administration. (2024a). Approved drug products with therapeutic equivalence evaluations: Orange Book. Silver Spring, MD: Author.
-
U.S. Food and Drug Administration. (2024b). Paragraph IV drug product and patent information. Silver Spring, MD: Author.
